Why is genetic testing required before larotrectinib treatment?

Larotrectinib is a targeted therapy for malignant tumors carrying NTRK gene fusions. In order to ensure the effectiveness and safety of the drug, genetic testing is an indispensable step before taking larotrectinib.

Genetic testing plays a vital role in cancer treatment, especially when selecting targeted therapies. For patients considering larotrectinib, the primary purpose of genetic testing is to confirm whether their tumors contain NTRK gene fusions. This type of gene fusion is widely found in various cancers such as infantile fibrosarcoma, adult soft tissue sarcoma, and thyroid cancer.

For genetic testing, it is usually necessary to obtain a tissue sample from the patient, such as tumor tissue obtained through a biopsy or after surgery, or a blood sample to detect circulating tumorDNA. These samples will be sent to professional laboratories for in-depth analysis to accurately determine whether NTRKgene fusion is present.

Once the presence of the NTRK gene fusion is confirmed in a patient's tumor, doctors can more accurately assess larotrectinib's likely efficacy in the patient. However, even if this gene fusion exists, not every patient is a candidate for larotrectinib. Doctors also need to consider the patient's overall health, past treatments, and individual needs to make the best treatment decision.

To sum up, genetic testing not only provides doctors with valuable information to better understand tumor characteristics, but also provides solid data support for formulating personalized treatment plans. Through genetic testing, we can ensure that patients receive the treatment that is best for them, thereby improving treatment effectiveness while ensuring patient safety.